NEOS Investment Management LLC Sells 960 Shares of Inari Medical, Inc. (NASDAQ:NARI)

NEOS Investment Management LLC trimmed its position in shares of Inari Medical, Inc. (NASDAQ:NARI) by 6.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,790 shares of the company’s stock after selling 960 shares during the quarter. NEOS Investment Management LLC’s holdings in Inari Medical were worth $755,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Inari Medical by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock valued at $287,354,000 after purchasing an additional 30,702 shares during the last quarter. Jennison Associates LLC boosted its position in Inari Medical by 11.8% in the 4th quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock valued at $90,014,000 after buying an additional 186,617 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Inari Medical by 9.1% in the 4th quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock valued at $54,546,000 after buying an additional 89,108 shares during the period. Bamco Inc. NY raised its position in shares of Inari Medical by 29.5% during the third quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock worth $41,493,000 after acquiring an additional 228,977 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Inari Medical by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 465,962 shares of the company’s stock valued at $23,787,000 after acquiring an additional 11,990 shares during the period. 90.98% of the stock is owned by institutional investors and hedge funds.

Inari Medical Price Performance

NARI opened at $79.97 on Monday. The company has a fifty day simple moving average of $79.87 and a 200 day simple moving average of $61.56. The stock has a market cap of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $79.99.

Insiders Place Their Bets

In related news, Director William Hoffman sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the completion of the transaction, the director now directly owns 238,987 shares in the company, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on NARI. BTIG Research reissued a “neutral” rating on shares of Inari Medical in a report on Wednesday, January 8th. Oppenheimer initiated coverage on shares of Inari Medical in a report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price objective on the stock. Baird R W lowered shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Wells Fargo & Company reissued an “equal weight” rating and issued a $80.00 price target (up previously from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, William Blair restated a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Inari Medical currently has an average rating of “Hold” and a consensus target price of $68.00.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.